- VGXI, Inc. has been accepted into the BioMap Consortium, which is focused on enhancing U.S. biomanufacturing capabilities and public health preparedness.
- The BioMap Consortium is supported by BARDA and includes over 200 member firms dedicated to securing medical supplies and developing countermeasures.
VGXI, Inc., a CDMO specialising in nucleic acid biopharmaceuticals, has announced its acceptance into the Biopharmaceutical Manufacturing Preparedness (BioMap) Consortium. This consortium, supported by the Biomedical Advanced Research and Development Authority (BARDA), aims to strengthen the United States’ biopharmaceutical manufacturing capacity and improve supply chain resilience to ensure readiness for public health emergencies.
With this membership, VGXI aligns itself with over 200 other firms committed to enhancing the nation’s biomanufacturing capabilities. The consortium’s efforts include securing necessary funding, expanding industrial output, and developing strategies to rapidly deliver biopharmaceutical products and related materials to civilian populations.
Commenting on this achievement, Young Park, CEO at VGXI, stated, “We are proud to be a part of the BioMap Consortium. Our demonstrated history of manufacturing solutions for public health allows VGXI to be a valuable contributor to this consortium and to support our fellow members and US-based biomanufacturing to address health-related threats to the nation’s public health.”
VGXI brings to the consortium its extensive experience in plasmid DNA manufacturing, boasting the world’s largest plasmid manufacturing capacity at 4000 litres. This capability positions VGXI to support the development of next-generation therapeutics across various stages, from preclinical research to commercial production.
 Overview of outsourcing trends 
